Jump to content

The largest ever global study into the safety of Covid-19 vaccines has been terminated just 13 months shy of completion, after becoming caught up in the Trump administration’s sweeping funding cuts.

The Global Vaccine Data Network, which was established in 2019 by the New Zealand-based vaccinologist Helen Petousis-Harris and the US-based vaccinologist Steven Black, has already produced some of the world’s most comprehensive studies on vaccine efficacy and safety, based on data from more than 300 million people.

The University of Auckland hosts the network, which collaborates with institutions and experts across the globe.

The groundbreaking five-year project to evaluate the safety of Covid vaccines across hundreds of millions of people received more than NZ$10m from the US Centers for Disease Control and Prevention (CDC) in 2021, but after a recent funding review by the so-called Department of Government Efficiency (Doge), it can no longer finish the project, Petousis-Harris said.

The network looks at data from millions of people to evaluate the effectiveness of vaccines, analyse risk and benefits and respond to issues such as vaccine hesitancy.

To do this requires “enormous study power, enormous populations and diversity”, said Petousis-Harris, who is an associate professor at the University of Auckland.

But funding for the global Covid vaccine safety project was “suddenly cut … without warning, without planning”, she told the Guardian.

Read full story

Source: The Guardian, 24 April 2025

0 Comments


Recommended Comments

There are no comments to display.


Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.